

REMARKS

Claims 36, 37, 65 and 67 have been amended herein. Support for the amendments can be found in the application as filed. No new matter has been added.

Claims 1-29, 32-35, 38-39, 50-52, 54-55, 57-64, 74-79, 84-94, 98-100, 104-106, 110-116 and 120-127 have been cancelled.

Claims 30-31, 36-37, 40-49, 53, 56, 65, 67, 72-73, 80-83, 95-97, 101-103, 107-109 and 117-119 remain in the case.

OBJECTIONS TO THE SPECIFICATION

1. The Examiner objected to the incomplete reference to the preparation of oligonucleotide primers for cloning a cDNA to a LDL receptor at page 31, line 20 of the disclosure. The Examiner suggested that this reference be deleted in view of the lack of disclosure of detection of LDL receptor-specific mRNA Northern blots using an LDL receptor cDNA in the disclosure. Both the added parenthetical statement and the reference to the LDL receptor have been deleted to accelerate allowance.

2. The Examiner's objection to claims 59 and 60 under 35 U.S.C. § 132(a) is rendered moot by the cancellation of these claims.

REJECTIONS UNDER 35 U.S.C. § 112 FIRST PARAGRAPH

The Examiner's rejections of claims 59, 60 and 120-127 under 35 U.S.C. § 112, first paragraph is rendered moot by the cancellation of these claims.

The Examiner's rejection of claims 59, 60, 120-122 and 124-126 under 35 U.S.C. § 112, first paragraph is rendered moot by the cancellation of these claims.

REJECTIONS UNDER 35 U.S.C. § 102

The Examiner's rejection of claims 59, 60, 120-122 and 124-126 under 35 U.S.C. § 102 as being anticipated by Brown et al., is rendered moot by the cancellation of these claims.

The Examiner is also advised that the trade-mark Ultrahyb™ was identified as such in the disclosure at page 31.

CONCLUSION

The rejections of the original claims are believed to have been overcome by the present remarks. From the foregoing, further and favorable action in the form of a Notice of Allowance is believed to be next in order, and such an action is earnestly solicited. No additional fee is believed necessary for consideration of this amendment. However, if one is, please charge it to Deposit Account 17-0055.

Respectfully submitted,

Institut de Recherches Cliniques de Montréal

by: Quarles & Brady, LLP



Ann E. Rabe
Reg. No. 56,697

Date: August 8, 2006

Tel.: (414) 277-5613
Fax: (414) 978-8712